Drug Trial Radar · NCT07811193
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Sep 11, 2026
Primary completion
Jun 30, 2028
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Vividion Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Bayer
- First posted
- Sep 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat people with advanced colorectal cancer. Colorectal cancer (cancer of the colon or rectum) is one of the most common cancers worldwide. Treatments include surgery, chemotherapy, radiotherapy, and immunotherapy; however, these treatments do not work for everyone, may cause serious adverse events or may stop working eventually. New treatments and treatment combinations are needed, especially for cancers that cannot be removed with surgery or that have spread to other parts of the body (called advanced or metastatic cancer). Cells normally repair themselves when mistakes happen as they divide. But in some people with cancer, the repair system does not work properly because of a problem called dMMR (deficient mismatch repair). As a result, mistakes build up in the cell's DNA, leading to a condition called MSI (microsatellite instability). Over time, these changes can cause cells to grow and behave abnormally, contributing to the development and growth of cancer. To survive, some cancer cells with dMMR or MSI rely on a protein called Werner helicase. This protein helps repair some of the DNA damage allowing them to keep growing. Because these cancer cells depend more on Werner helicase than healthy cells, blocking this protein may help stop cancer cells from surviving while having less effect on healthy cells. The study drug, VVD-133214, is designed to block the Werner helicase protein. Blocking this protein may help stop cancer cells from growing, while causing less harm to healthy cells. VVD-133214 is being studied in combination with pembrolizumab, an approved immunotherapy that helps the immune system recognize and attack cancer cells. This study will test the combination of VVD-133214 and pembrolizumab in people with advanced colorectal cancer with MSI and/or dMMR who have not yet received treatment for their advanced disease. The study aims to find the best dose of VVD-133214 in combination with pembrolizumab and to test whether the combination is more effective than pembrolizumab alone. Participants will receive treatment with VVD-133214 for as long as it can help them and does not cause serious adverse events. Treatment with pembrolizumab will stop after two years. Participants can also stop treatment at any time. During the study, participants will have regular visits with the study doctor for tests, scans, and check-ups. These visits help check how well the cancer is responding to the treatment and monitor the participants' health. The study will also monitor adverse events, which are any new or worsening medical problems that can happen during the study. Doctors record all adverse events, irrespective of whether the study doctor believes they are related to the study treatments, to help ensure participants' safety throughout the study. After stopping treatment, participants will return for follow-up visits: 30 days after their last dose of VVD-133214 and/or 100 days after their last dose of pembrolizumab. After that, participants will have long-term follow-up visits every 90 days for as long as they agree to continue participating in follow-up.
Conditions
- Colorectal Adenocarcinoma
Interventions
VVD-133214Drug
VVD-133214 will be administered orally
PembrolizumabDrug
Pembrolizumab will be administered by intravenous infusion (IV) every three weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Landmark progression-free survival (PFS) rate at 6 months, as assessed by the investigatorTime frame: From start of study treatment until end of follow-up (up to approximately 36 months)
Locations
123 sites in 22 countries. Site status is shown where the registry gives one.
University of Arizona Cancer Center - North Campus
Tucson, Arizona · Not yet recruiting
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan · Not yet recruiting
Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit
Detroit, Michigan · Not yet recruiting
Mary Babb Randolph Cancer Center
Morgantown, West Virginia · Not yet recruiting
Hospital Italiano de Buenos Aires
Buenos Aires, Buenos Aires, Argentina · Recruiting
Centro Medico Fleischer
Buenos Aires, Buenos Aires, Argentina · Recruiting
Instituto Alexander Fleming
Buenos Aires, Buenos Aires, Argentina · Not yet recruiting
Investigaciones Oncológicas C Colón
Mar del Plata, Buenos Aires, Argentina · Not yet recruiting
Sanatorio Allende | Departamento de Investigación Clínica
Córdoba, Córdoba Province, Argentina · Not yet recruiting
Fundación Intecnus
Bariloche, Río Negro Province, Argentina · Not yet recruiting
Sanatorio Parque - Oncology
Rosario, Santa Fe Province, Argentina · Not yet recruiting
Institut Jules Bordet - Clinique D'Oncology
Brussels, Brussels Capital, Belgium · Not yet recruiting
UZ Leuven - Digestive oncology
Leuven, Flemish Brabant, Belgium · Not yet recruiting
CHU Helora - Hopital de La Louvière - Site Jolimont - Oncology department
La Louvière, Hainaut, Belgium · Not yet recruiting
UZ Gent - Digestive Oncology
Ghent, Oost-Vlaaanderen, Belgium · Not yet recruiting
AZ Delta - Digestive oncology
Roeselare, West-Vlaanderen, Belgium · Not yet recruiting
Hospital Evangélico de Cachoeiro de Itapemirim
Vitória, Espírito Santo, Brazil · Not yet recruiting
Hospital Araujo Jorge Associaçao de Combate ao Cancer em Goias
Goiânia, Goiás, Brazil · Not yet recruiting
Nucleo de Ensino e Pesquisa do Hospital de Clinicas de Ijuí
Ijuí, Rio Grande do Sul, Brazil · Not yet recruiting
Unidade de Pesquisas Clinicas em Oncologia
Pelotas, Rio Grande do Sul, Brazil · Not yet recruiting
NAIC - Instituto do Cancer
Bauru, São Paulo, Brazil · Not yet recruiting
Fundacao Pio XII - Hospital de Cancer de Barretos
Jaú, São Paulo, Brazil · Not yet recruiting
Instituto do Cancer do Estado de Sao Paulo
São Paulo, São Paulo, Brazil · Not yet recruiting
Hospital Sirio Libanes - Oncology_Sao Paulo
São Paulo, São Paulo, Brazil · Not yet recruiting
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China · Not yet recruiting
Beijing Cancer Hospital - Oncology Department
Beijing, Beijing Municipality, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
The Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Wuhan, Hubei, China · Not yet recruiting
Shandong University - Shandong Cancer Hospital
Jinan, Shandong, China · Not yet recruiting
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Not yet recruiting
West China Hospital Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
Yunnan Cancer Hospital
Kunming, Yunnan, China · Not yet recruiting
Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department
Hangzhou, Zhejiang, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
CHRU de Besancon - Hopital Jean Minjoz - Medical Oncology
Besançon, Bourgogne-Franche-Comté, France · Not yet recruiting
Unicancer Dijon - Centre Georges Francois Leclerc - Oncologie medicale
Dijon, Bourgogne-Franche-Comté, France · Not yet recruiting
CHU Brest - Hopital La Cavale Blanche - service oncologie medicale
Brest, Brittany Region, France · Not yet recruiting
Unicancer Marseille - Institut Paoli-Calmettes - Oncologie medicale
Marseille, Provence-Alpes-Côte d'Azur Region, France · Not yet recruiting
Showing 40 of 123 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.